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Background: The outcome after a repeat hepatectomy for recurrent colorectal liver metastases (CLM)
is not well defined. The present study examined the morbidity, mortality and long-term survivals after a
repeat hepatectomy for recurrent CLM.
Methods: Data on patients who underwent surgery for recurrent CLM between 1993 and 2009 were
retrospectively evaluated. Patients who underwent radiofrequency ablation at the time of first treatment
or at recurrence of CLM were excluded.
Results: Forty-three patients underwent a repeat hepatectomy for recurrent CLM. At the time of recur-
rence, patients had a median of 1 (1–3) lesions and the median tumour size was 2 (0.5–8.7) cm. The
post-operative morbidity and mortality rates were 12% and 0%, respectively. After a median follow-up of
33 months from a repeat hepatectomy, 5-year overall and progression-free survival rates were 73% and
22%, respectively. Using multivariate analysis, the largest initial CLM5 cm and positive surgical margins
at initial resection were independently associated with a worse survival after surgery for recurrent CLM.
Positive surgical margins at repeat hepatectomy were a predictive factor for an increased risk of further
recurrence.
Discussion: A repeat hepatectomy for recurrent CLM was associated with excellent survival, low
morbidity and no mortality. Surgeon-controlled variables, including margin-negative resection at first and
repeat hepatectomy, contribute to good oncological outcome.
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Introduction
Liver resection has been shown to effectively prolong survival in
patients with colorectal liver metastases (CLM) and is widely
accepted as the best treatment option in patients with resectable
disease.1,2 Although 5-year overall survival rates can reach 58%,1,2
up to 57% of patients develop recurrence after resection of CLM.3
The liver is the most common site of recurrence after resection of
CLM; most recurrences present as new lesions, whereas local
recurrences at the surgical margin are uncommon even in cases of
microscopic invasion at the margin.4–6 In selected patients with
liver-only recurrence, a repeat hepatectomy has been reported to
be feasible and associated with good outcomes.7–12 In particular, a
repeat hepatectomy can be associated with prolonged survival,
with 5-year survival rates as high as 85%.9,10,13 However, although
previous studies have evaluated factors associated with favourable
outcome after a repeat hepatectomy,12 it is still not well defined
whether prolonged survival is the result of oncological factors
only or of surgeon-controlled factors such as completeness of
resection.14
The present study examined the post-operative and oncological
outcomes of patients who underwent a repeat hepatectomy for
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recurrent CLM. Predictive factors associated with overall and
progression-free survival in patients who underwent surgical
treatment of recurrent CLM were investigated.
Patients and methods
Study inclusion criteria
Data on 115 consecutive patients who underwent a laparotomy
for recurrent CLM after initial resection or radiofrequency abla-
tion (RFA) at The University of Texas MD Anderson Cancer
Center between December 1993 and December 2009 were retro-
spectively evaluated. For the present study, only patients who
underwent a repeat hepatectomy were selected. Patients who had
RFA at the time of first surgery or as a treatment of recurrent CLM
were excluded. All patients had pathologically proven initial and
recurrent CLM. The present study was approved by the Institu-
tional Review Board of MD Anderson Cancer Center.
Diagnosis of recurrent CLM and
pre-operative assessment
The diagnosis of recurrent CLM was made using helical-
computed tomography (CT) with liver protocol (rapid injection
of 150 ml of intravenous contrast material with image reconstruc-
tion of 2.5–5 mm through the liver) or magnetic resonance
imaging (MRI). Figure 1 shows abdominal CT images of a patient
before and after the first hepatectomy for CLM and a repeat hepa-
tectomy for recurrent CLM. Recurrent CLM was defined as local
recurrence when it occurred at the surgical margin of a prior
resection,4 while all other relapses in the liver were defined as new
lesions. Beginning in 1998, 9-fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) was used in the majority of patients
to rule out extrahepatic disease and to confirm the metastatic
nature of atypical lesions.15 When recurrent CLM was suspected
but not confirmed after the initial imaging work-up, a new evalu-
ation including CT and FDG-PET was generally repeated approxi-
mately 1 month later to detect additional changes. A tumour
biopsy was performed when indicated to secure the diagnosis of
recurrence. When the diagnosis of recurrence was confirmed, the
patient’s physical status was carefully evaluated. In most patients,
the decision whether surgery for recurrent CLM was indicated was
made during a multidisciplinary meeting that included hepatobil-
iary surgeons, imaging radiologists, interventional radiologists
and medical oncologists. The decision whether to administer pre-
operative chemotherapy was based on the extent of recurrent
CLM, the presence of extrahepatic disease, and previous response
to and toxic effects of chemotherapy, at the multidisciplinary
team’s discretion.
Surgical procedure
Liver resections were performed only with curative intent, i.e. only
if it was believed that all tumour deposits could be completely
resected. During a laparotomy, the peritoneal cavity was inspected
to rule out extrahepatic recurrence. Palpation and intra-operative
ultrasonography were carried out in all patients to better define
the location of the metastases in the liver and their relationship
with portal pedicles and hepatic veins. A parenchymal transection
was performed using an ultrasonic dissector, and haemostasis was
Figure 1 Large solitary colorectal liver metastasis (CLM) involving segments VI, VII and VIII (a) at diagnosis, (b) 3 months after resection (right
hepatectomy), (c) at the time of recurrence and (d) 20 months after a repeat hepatectomy, showing no evidence of disease
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achieved with a saline-linked cautery as previously described.16,17
A major hepatectomy was defined as a liver resection comprising
three or more contiguous liver segments. Consequently, a minor
hepatectomy was defined as resection of less than three liver
segments.
Post-operative period
Post-operative morbidity and 30-day and 90-day mortality rates
were studied. Major post-operative complications were defined as
complications of grade 3 or higher in the Clavien–Dindo classifi-
cation (i.e. necessitating a surgical, endoscopic or radiological
procedure).18 Post-operative liver insufficiency was defined as a
post-operative bilirubin peak level 7 mg/dl.19 All resection
specimens were histologically evaluated and the surgical margins
were examined for tumour cell invasion. The margin width was
defined as the distance between the tumour and the closest inked
section as previously described.4 R0 resection was defined as a
complete tumour resection with surgical margins microscopically
negative for tumour cells.
After a hepatectomy, the use of post-operative chemotherapy
was considered by the multidisciplinary team of oncologists and
surgeons; factors taken into account included the completeness of
the resection, the morphological and pathological response to
pre-operative chemotherapy, the extent and the toxicity of previ-
ous chemotherapy, if any. In patients with a further liver recur-
rence after a repeat hepatectomy, the feasibility of a third liver
resection versus the utility of other interventions was determined
on the basis of the extent of prior resections, extent of recurrent
disease, and the volume and function of the remnant liver. No
fixed number or size criteria were used to determine resectability
at the first or any subsequent liver resection.
Statistical analysis
Quantitative and qualitative variables were expressed as median
(range) and frequency. Comparisons between groups were analy-
sed with the c2- or Fisher’s exact test for proportions and the
Mann–Whitney U-test for continuous variables as appropriate.
Overall and progression-free survival rates were calculated from
the time of a repeat hepatectomy to the date of last follow-up and
date of recurrence, respectively; they were calculated using the
Kaplan–Meier method and compared using log-rank tests. For
detection of factors associated with survival in patients who
underwent a repeat hepatectomy for recurrent CLM, univariate
analysis was used to examine the relationship between survival
and the following variables: location of the primary tumour
(colon vs. rectum); status of regional lymph nodes at the time of
diagnosis of the primary tumour (positive vs. negative); status of
the surgical margins on microscopic analysis at the initial and
repeat hepatectomy (positive for tumour cells vs. negative); timing
of the detection of the initial CLM (synchronous [present at the
time of resection of the primary tumour] vs. metachronous); the
number of initial CLM (single vs. multiple); size of the largest
initial CLM (<5 vs. 5 cm); time to recurrence (12 vs. <12
months); type of recurrence (local vs. new lesion); carcinoembry-
onic antigen (CEA) plasma level at the time of the resection of the
recurrent CLM (5 vs. >5 ng/ml); number of recurrent CLM
(single vs. multiple); size of the largest recurrent CLM (<3 vs.
3 cm); extent of the resection (major vs. minor); extension of
the CLM resection to an adjacent organ (yes vs. no); intra-
operative blood transfusion (required vs. not); post-operative
complications (present vs. absent); and post-operative chemo-
therapy for the recurrent CLM (administered vs. not). All vari-
ables associated with survival with a P-value less than 0.15 in
univariate proportional hazards models were subsequently
entered into a Cox multivariate regression model with backward
elimination. P-values less than 0.05 were considered statistically
significant.
Statistical analysis was performed using the statistical software
package SPSS version 17.2 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Among the 115 patients who had surgical treatment of recurrent
CLM between 1993 and 2009, 43 underwent a repeat hepatectomy
for recurrent CLM after an initial liver resection and fulfilled the
inclusion criteria. The number of patients who were treated with
a repeat hepatectomy increased over time. Most repeat hepatec-
tomies were performed in 2008 and 2009 (Fig. 2). Pre-operative
characteristics of these 43 patients are summarized in Table 1.
Nineteen patients were older than 55 years and 31 patients were
male. At the time of initial diagnosis of CLM, 19 patients had
multiple CLM and 7 patients had tumours larger than or equal to
5 cm. At first treatment of CLM, 24 patients underwent a major
hepatectomy and 19 patients were treated with minor liver resec-
tion. The majority of patients (24/43) developed recurrent CLM
within 12 months after the first hepatectomy for CLM. At the time
of recurrence, patients had limited recurrent disease in the liver:
36 patients had solitary liver recurrence and 31 patients had a
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Figure 2 Time evolution of the number of patients undergoing a
repeat hepatectomy for recurrent colorectal liver metastasis (CLM) at
the MD Anderson Cancer Center
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maximum tumour size <3 cm. Initially treated and recurrent
CLM had similar median sizes (2 [0.5–13] vs. 2 [0.5–8.7] cm,
respectively; P = 0.243), but the number of recurrent lesions was
lower than the number of CLM resected at the initial hepatectomy
(1 [1–3] vs. 1 [1–10], respectively; P = 0.002).
Intra-operative and post-operative characteristics
Intra-operative and post-operative characteristics for a repeat
hepatectomy are summarized in Table 1. Five patients had a major
liver resection, including two extended left hepatectomies, two
right hepatectomies and one extended right hepatectomy. All
other patients had minor resections. Five patients developed post-
operative complications after a repeat hepatectomy including
pleuropulmonary complications (2), superficial wound infections
(2), and atrial fibrillation (1); none had a post-operative liver
insufficiency or a major complication requiring re-operation or
percutaneous drain placement. Post-operative 30-day and 90-day
mortality rates were both 0%.
Survival
At a median (range) follow-up interval of 33 (6–149) months after
a repeat hepatectomy, 3- and 5-year overall survival rates were
82% and 73%, respectively. Three- and 5-year progression-free
survival rates were 22% and 22%, respectively (Fig. 3). Thirty
patients developed further recurrence, and the median time to
recurrence after a repeat hepatectomy was 7 (1–32) months.
Recurrent lesions were identified in the liver (15), lung (9), peri-
toneum (4), lymph nodes (3), and bones (1). Two patients had
simultaneous recurrences in the liver and lung. Ten patients
received local therapy for their further recurrence: five were
treated with a third hepatectomy, three with RFA, and two with
resection of lung metastases.
Predictors of outcome
In univariate analysis, the largest initial CLM 5 cm (P = 0.004)
and positive surgical margins at initial resection (P = 0.039) were
associated with worse overall survival after resection of recurrent
CLM. In multivariate analysis, both the largest initial CLM5 cm
(hazard ratio [HR] = 12.36, 95% confidence interval [CI] = 2.12–
72.03, P = 0.005) and positive surgical margins at initial resection
(HR = 9.55, 95% CI = 1.59–57.38, P = 0.014) were independently
associated with worse survival after surgery for recurrent CLM
(Table 2). Positive surgical margins at repeat hepatectomy pre-
dicted progression-free survival in univariate analysis (P = 0.018)
and was the only factor identified in multivariate analysis to be
independently associated with an increased risk of further recur-
rence (HR = 3.00, 95% CI = 1.15–7.86, P = 0.025) (Table 3).
Discussion
The present study confirms that a repeat hepatectomy for recur-
rence of CLM after a first resection is feasible and safe and is
associated with prolonged survival in selected patients. In this
study, a 73% 5-year overall survival rate was observed. In addition
there were no major complications or post-operative mortality.
These excellent results were achieved in spite of the fact that 26
out of 43 patients had synchronous CLM, a factor associated
with a high risk for poor outcome.20,21 Previous studies sug-
gested the feasibility of this approach,8,10,12,22 but the reality is that
Table 1 Clinicopathological characteristics and outcomes of
patients who underwent a repeat hepatectomy for recurrent colorec-
tal liver metastasis (CLM)
Characteristic Number (%)
of patients
(n = 43)
Initial diagnosis of CLM
Median age (range) 55 (32–74) years
Gender (M/F) 31/12
Median body mass index (range) 27 (19–37) kg/m2
Rectal primary tumour 17 (40)
Node-positive primary tumour 36 (84)
Positive surgical margin 4 (9)
Liver metastases
Synchronous (vs. metachronous) 24 (56)
Median number of CLM (range) 1 (1–10)
Median maximum CLM diameter (range) 2 (0.5–13) cm
Recurrent CLM
Median time to recurrence after first
hepatectomy (range)
11 (1–147) months
Liver metastases
Median number of CLM (range) 1 (1–3)
Median maximum CLM diameter (range) 2 (0.5–8.7) cm
New lesions 42 (98)
Local recurrence 1 (2)
Pre-operative chemotherapy 19 (44)
Post-operative chemotherapy 27 (63)
Type of resection
Major liver resection (3 liver segments) 5 (12)
Resection of CLM extension to
adjacent organ(s)
2 (5)
Positive surgical margin 6 (14)
Median CEA before a repeat hepatectomy 2 (1-63) ng/ml
Median estimated blood loss (range) 250 (50–1100) ml
Transfusion requirement 2 (5)
Median operating time (range) 183 (63–546) min
Post-operative mortality 0
Post-operative morbidity 5 (12)
Major complication ratea 0
Median length of hospital stay (range) 6 (3–10) days
Values in the table are the number of patients (percentage) unless
otherwise indicated.
aMajor complication was defined as requiring surgical, endoscopical or
radiological intervention.
CLM, colorectal liver metastasis: CEA, carcinoembryonic antigen.
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a repeat hepatectomy creates a number of technical challenges10
combining the difficulties associated with surgery on the often
fragile, regenerative liver and those of intra-abdominal adhesions
between the liver and regional structures, including the dia-
phragm, that are related to first resection. During the past decade,
however, the safety of a liver resection has improved and, an
increasing number of patients with hepatic malignancies are
treated surgically. In spite of this increase in re-resection over
time, morbidity remains low, and major morbidity and mortality
can be minimized in carefully selected patients. Improvements in
surgical technique and peri-operative care probably contribute to
these results.16,23 The wide use of pre-operative chemotherapy in
the study patients (19/43), which has been previously associated
with increased post-operative morbidity,24–26 did not have a nega-
tive impact on the surgical results, underlining the feasibility of
this approach in this subset of patients.
This is a timely discussion, because RFA has been proposed as
an alternative for the treatment of recurrent CLM27,28 because of
its low morbidity and mortality rates. In the current series, the
influence of post-operative morbidity on long-term outcome
cannot be used as an argument to recommend RFA rather than
resection as morbidity was low. Therefore re-resection should be
considered for the treatment of recurrent CLM based on the
established long-term results of liver resection1,29 and the excellent
overall survival achieved in the present study. However, a more
comprehensive comparison between RFA and surgery is required
so that definitive conclusions regarding the local recurrence rate
after treatment of recurrent CLM can be drawn.
Although excellent survival outcomes were observed in the 43
patients undergoing a repeat hepatectomy, further recurrence
remains a major oncological challenge; in the present study, 30 of
the patients developed further recurrence. Candidates for iterative
resection of recurrent CLM have been selected by the sequence of
treatments as patients with slowly progressing disease and favour-
able tumour biology, as those with extensive recurrence are not
candidates for iterative intervention. The present study found the
initial tumour size larger or equal to 5 cm and positive surgical
margins at first resection of CLM to be predictive factors for
shorter survival after a repeat hepatectomy. A large tumour size
has been associated with shorter survival in patients undergoing a
primary resection of CLM,20,30 and the finding that tumour size
also affects outcome after a repeat hepatectomy suggests that it
may be a surrogate factor for tumour dissemination in the liver
that may remain undetected with current pre-operative and intra-
operative imaging methods. Such residual, undetected disease
may explain the high risk of developing new liver lesions, leading
to a low rate of overall survival. However, patients were selected
not on the basis of tumour-related factors such as size (or
number) but rather on the potential for safe resection of all
tumour deposits while leaving an adequate liver remnant. Indeed,
tumour size, although it may be a prognostic factor, is not used to
select patients for initial liver resection.31 In patients with recur-
rent CLM, the authors would not propose that initial or recurrent
tumour size should be used to select patients for surgery for
otherwise resectable tumours, as prolonged survival can be
achieved.
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Figure 3 Overall and progression-free survival in 43 patients who underwent a repeat hepatectomy for recurrent colorectal liver metastasis
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Table 2 Univariate and multivariate analysis of factors associated with overall survival in patients who underwent a repeat hepatectomy for
recurrent CLM
Predictor of overall survival n (%) 5-year survival (%) Univariate analysis
P-value
Multivariate analysisa
P-value HR (95% CI)b
Initial diagnosis of CLM
Primary tumour 0.379
Colon 26 (60) 86
Rectum 17 (40) 58
Regional lymph nodes for the primary tumour 0.996
Positive 36 (84) 72
Negative 7 (16) 80
Surgical margin 0.039 0.014 9.55 (1.59-57.38)
Positive 4 (9) 38
Negative 39 (91) 76
Timing of detection of CLM 0.732
Synchronous 24 (56) 75
Metachronous 19 (44) 71
Number of CLM 0.321
Single 24 (56) 82
Multiple 19 (44) 59
Size of the largest CLM 0.004 0.005 12.36 (2.12-72.03)
5 cm 7 (16) 24
<5 cm 36 (84) 84
Recurrent CLM
Time to recurrence after the first hepatectomy 0.221
<12 months 24 (56) 66
12 months 19 (44) 82
Type of recurrence 0.398
Local 1 (2) 0
New lesion 42 (98) 72
CEA plasma level 0.755
>5 ng/ml 13 (30) 74
5 ng/ml 30 (70) 68
Number of CLM 0.136 0.921 1.10 (0.18-6.74)
Single 36 (84) 79
Multiple 7 (16) 48
Size of the largest CLM 0.890
3 cm 12 (28) 72
<3 cm 31 (72) 80
Extent of resection 0.318
Major 5 (12) 70
Minor 38 (88) 100
Resection of the CLM extension to adjacent organ(s) 0.413
Yes 2 (5) 50
No 41 (95) 74
Blood transfusion 0.230
Yes 2 (5) 0
No 41 (95) 77
Post-operative complication 0.658
Yes 5 (12) 75
No 38 (88) 74
Surgical margin 0.969
Positive 6 (14) 83
Negative 37 (86) 73
Post-operative chemotherapy 0.453
Yes 27 (63) 57
No 16 (37) 87
aCox's regression multivariate analysis included all variables with a P-value less than 0.15 in univariate analysis.
bCI, confidence interval; HR, hazard ratio.
CLM, colorectal liver metastasis; CEA, carcinoembryonic antigen.
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Table 3 Univariate and multivariate analysis of factors associated with progression-free survival in patients who underwent a repeat
hepatectomy for recurrent CLM
Predictor of overall survival n (%) 5-year survival (%) Univariate analysis
P-value
Multivariate analysisa
P-value HR (95% CI)b
Initial diagnosis of CLM
Primary tumour 0.666
Colon 26 (60) 23
Rectum 17 (40) 21
Regional lymph nodes for the primary tumour 0.912
Positive 36 (84) 22
Negative 7 (16) 30
Surgical margin 0.583
Positive 4 (9) 0
Negative 39 (91) 24
Timing of CLM 0.354
Synchronous 24 (56) 22
Metachronous 19 (44) 25
Number of CLM 0.159
Single 24 (56) 25
Multiple 19 (44) 17
Size of the largest CLM 0.597
5 cm 7 (16) 29
<5 cm 36 (84) 21
Recurrent of CLM
Time to recurrence after the first hepatectomy 0.489
<12 months 24 (56) 22
12 months 19 (44) 22
Type of recurrence 0.689
Local 1 (2) 0
New lesion 42 (98) 23
CEA plasma level 0.144 0.058 2.63 (0.97-7.13)
>5 ng/ml 13 (30) 1
5 ng/ml 30 (70) 31
Number of CLM 0.766
Single 36 (84) 22
Multiple 7 (16) 18
Size of the largest CLM 0.561
3 cm 12 (28) 25
<3 cm 31 (72) 22
Extent of resection 0.443
Major 5 (12) 33
Minor 38 (88) 20
Resection of CLM extension to adjacent organ(s) 0.549
Yes 2 (5) 50
No 41 (95) 20
Blood transfusion 0.815
Yes 2 (5) 0
No 41 (95) 22
Post-operative complication 0.531
Yes 5 (12) 40
No 38 (88) 18
Surgical margin 0.018 0.025 3.00 (1.15-7.86)
Positive 6 (14) 0
Negative 37 (86) 26
Post-operative chemotherapy 0.250
Yes 27 (63) 17
No 16 (37) 33
aCox's regression multivariate analysis included all variables with a P-value less than 0.15 in univariate analysis.
bCI, confidence interval; HR, hazard ratio.
CLM, colorectal liver metastasis; CEA, carcinoembryonic antigen.
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The present study demonstrates that positive surgical margins
at an initial hepatectomy, a known risk factor for recurrence after
the index liver resection,30 is associated with poorer overall sur-
vival after a subsequent hepatectomy. Although prolonged sur-
vival has been reported in patients with positive surgical margins
who received pre-operative chemotherapy,5,6 margins of resection,
which are under the surgeon’s control, have a strong impact on
the ultimate post-surgical patient outcome. That being said, close
or positive margins may occur as a result of extensive or infiltra-
tive disease representing a surrogate factor of unfavourable
tumour biology, yet this finding reiterates that, even in the era of
modern and effective chemotherapy, the achievement of negative
surgical margins remains a primary objective of the surgical
therapy of CLM.
In spite of the good survival outcome, a high recurrence rate
after a repeat hepatectomy was observed. The relative discrepancy
between the high overall survival rate and significant risk for
further recurrence may be explained by the fact that a third of the
patients who developed further recurrence after a repeat hepate-
ctomy were treated with surgery or local therapy including RFA.
Again, as these patients are likely to recur, the use of an aggressive
oncosurgical approach probably contributes to prolonged sur-
vival. Among prognostic factors related to the second hepatec-
tomy, only negative surgical margins were associated with a
decreased risk of further recurrence. To date and in the absence of
other significant variables, the ability to achieve negative margins
is probably the main factor that should be taken into account
when selecting patients for re-resection; oncological outcomes for
patients with positive surgical margins at re-resection are dismal
(0% 5-year progression-free survival). Moreover, just as the liver is
the most common site of recurrence after primary resection of
CLM,3 the liver is a very common site of relapse after a repeat
hepatectomy for recurrent CLM as well (15/30). The present
finding reinforces the difficulty of completely eradicating the
disease using a combination of surgery and systemic treatment.
Thirty out of 43 patients re-recurred after a repeat hepatectomy in
spite of the fact that 20 out of these 30 patients received post-
operative chemotherapy. Adjuvant, liver-directed therapy, includ-
ing hepatic artery infusion and radioembolization, have not been
evaluated and may be tested to better control occult disease pro-
gression in the liver in this cohort. An unstudied alternative could
be more intensive systemic chemotherapy, including monoclonal
antibodies targeting the vascular endothelial growth factor (beva-
cizumab) or the epidermal growth factor receptor (cetuximab,
panitumumab), in spite of the paucity of evidence that these
agents reduce recurrence rates compared with chemotherapy
without targeted agents in stage III colorectal cancer.32
This retrospective analysis of a prospective database has limi-
tations, as the treated cohort may represent a selection of patients
with favourable tumour biology; patients who developed unresec-
table recurrence after an initial resection were not included.
However, the comparison with non-operated patients may not be
appropriate, as the study aim was not to propose this approach in
all patients with recurrent CLM but to provide tools to help in the
selection of candidates for a repeat hepatectomy.
In conclusion, these data reinforce the utility of a repeat hepa-
tectomy for recurrent CLM, as a safe treatment associated with
excellent long-term survival. The additional finding that negative
surgical margins at both the initial and repeat hepatectomy are the
predominant prognostic factors reinforces the critical contribu-
tion of careful surgical planning and precise tumour localization
during resection to optimize oncological outcomes and reduce
recurrence risk.
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